Conference Coverage

Poor NAFLD outcomes with increased VCTE-measured liver stiffness


 

FROM THE LIVER MEETING

Progression definition questioned

Following the presentation, Nezam Afdhal, MD, chief of the division of gastroenterology, hepatology, and nutrition at Beth Israel Deaconess Hospital in Boston, questioned how 25% of patients who had biopsy-proven cirrhosis could progress to LSM-defined cirrhosis.

Dr. Gawrieh said that, according to inclusion criteria, the patients could not have LSM-defined cirrhosis with the sensitivity cutoff of 12.1 kPa, and that of the 10 patients with baseline cirrhosis in the cohort, all had LSM of less than 12.1 kPa. However, he admitted that because those 10 patients were technically not progressors to cirrhosis, they should have been removed from the analysis for clinical outcomes.

Mark Hartman, MD, a clinical researcher at Eli Lilly and Company in Indianapolis, said the study is valuable but noted that those patients who progressed tended to have higher LSM at baseline as well as a higher [fibrosis-4 score].

Dr. Gawrieh added that the investigators are exploring variables that might explain progression to cirrhosis among patients without high baseline liver stiffness, such as alcohol use or drug-induced liver injury.

The study was supported by the National Institutes of Health and the NASH Clinical Research Network institutions. Dr. Gawrieh disclosed research grants from NIH, Zydus, Viking, and Sonic Incytes, and consulting for TransMedics and Pfizer. Dr. Afdhal and Dr. Hartman reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Few hepatitis C patients receive timely treatment: CDC
Federal Practitioner
Ultrasound on par with CT for evaluating sarcopenia in patients with cirrhosis
Federal Practitioner
Pervasive ‘forever chemical’ linked to liver cancer
Federal Practitioner
Hep C, HIV coinfection tied to higher MI risk with age
Federal Practitioner
FDA okays terlipressin (Terlivaz) injection for hepatorenal syndrome
Federal Practitioner
COVID tied to spike in deaths in chronic liver disease with diabetes
Federal Practitioner
FDA rejects bulevirtide for hepatitis D
Federal Practitioner
Low-carb diet aids weight loss in liver transplant recipients with obesity
Federal Practitioner
Noninvasive tests may provide prognostic value in NAFLD
Federal Practitioner
Liver disease-related deaths rise during pandemic
Federal Practitioner